Phase I Study of HAL Formulations Applied to the Cervix in Healthy Volunteers

This study has been terminated.
Information provided by:
Photocure Identifier:
First received: July 3, 2007
Last updated: January 15, 2009
Last verified: January 2009
The purpose of the study is to determine the most effective formulation of HAL for release of hexaminolevulinate to the cervical epithelium at different doses.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Phase I Hexaminolevulinate (HAL) Dose-Finding Study Applying Different Formulations to the Cervix in Healthy Volunteers

Further study details as provided by Photocure:


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy, pre-menopausal female volunteers

Exclusion Criteria:

  • Acute or chronic disease which could influence the study results
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00496171

Riks-Radium University Hospital
Oslo, Norway
Sponsors and Collaborators
Principal Investigator: Claes G Tropé, MD PhD Riks-Radium University Hospital
  More Information

No publications provided Identifier: NCT00496171     History of Changes
Other Study ID Numbers: PC CE102/07
Study First Received: July 3, 2007
Last Updated: January 15, 2009
Health Authority: Norway: Norwegian Medicines Agency
Norway:National Committee for Medical and Health Research Ethics processed this record on November 25, 2015